Eye­ing quick ap­proval, Ab­b­Vie of­fers a close-up on their pres­by­opia drug da­ta

Ab­b­Vie picked up some bonus points ear­li­er this year as one of its pipeline adds from the $63 bil­lion Al­ler­gan buy­out hit its top-line marks. And now the re­searchers have pro­duced the de­tailed da­ta on the case they are mak­ing with reg­u­la­tors, with an eye on a ma­jor new mar­ket and a hoped-for ap­proval be­fore New Year’s.

AGN-190584 is aim­ing to be the first easy-on eye­drop for pres­by­opia, a com­mon ail­ment for large num­bers of peo­ple who find it hard­er and hard­er to read things like a watch or cell phone close up. Any­one who’s held a book out at arm’s length in or­der to read it will be very fa­mil­iar with the con­di­tion, if not the ex­act di­ag­no­sis.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters